Navigation Links
Compound used to block cholesterol could also kill breast cancer, MU researcher finds

COLUMBIA, Mo. A University of Missouri researcher believes there could be a new drug compound that could kill breast cancer cells. The compound might also help with controlling cholesterol.

Salman Hyder, the Zalk Endowed Professor in Tumor Angiogenesis and professor of biomedical sciences in the College of Veterinary Medicine and the Dalton Cardiovascular Research Center, and his research team discovered that a small molecule, Ro 48-8071, initially developed for controlling cholesterol synthesis "dramatically destroys" human breast cancer cells. This development was discovered as Hyder's research team was investigating PRIMA-1, a drug that targets a common mutated gene in human breast cancer cells, and kills tumor cells.

During the course of the study, Xiaoquin Zou, an assistant professor in the MU Department of Physics and Astronomy, compared the chemistry of PRIMA-1 binding to thousands of proteins using a software program she developed called MDock. Hyder and Zou found that PRIMA-1 showed excellent binding properties to a protein called oxidosqualene cyclase, (OSC) that is known to be important for producing cholesterol. This led Hyder's team to investigate whether known OSC inhibitors, such as Ro 48-8071, developed to stop cholesterol production, also killed breast cancer cells.

"We had been working with PRIMA-1 for some time, and what we didn't quite understand is exactly how it killed tumor cells," Hyder said. "With the current findings, we think it's possible that one mechanism utilized by PRIMA-1 to kill cancer cells may include shutting down cholesterol synthesis, but we still don't know for certain if that's the case. What we do know is that Ro 48-8071 does stop cholesterol synthesis, and it proved to be just as effective in destroying cancer cells as PRIMA-1, without harming other normal breast cells, which is a big advantage."

While there are still many studies to complete, including testing on humans, Hyder believes there are great possibilities in using Ro 48-8071 as a treatment for breast cancer. Hyder gives equal credit to MU colleagues Xiaoqin Zou, Sam Grinter, graduate student in physics; Yayun Liang, assistant professor and Dalton researcher and Sheng-You Huang, research associate.

"This is a good example of interdisciplinary research, where colleagues with different expertise collaborated to find targets and verify their use for breast cancer therapy. We couldn't have achieved this finding with each of us working on our own," Hyder said.


Contact: Steven Adams
University of Missouri-Columbia

Related medicine news :

1. Red wine compound increases anti-tumor effect of rapamycin
2. Scripps Research compound blocks brain cell destruction in Parkinsons disease
3. Bioactive compounds in berries can reduce high blood pressure
4. Finnish researchers find a compound that prevents the growth of prostate cancer cells
5. Drug-like compound stops thyroid overstimulation in early NIH studies
6. Compound that blocks sugar pathway slows cancer cell growth
7. New compounds may treat both alcohol and cigarette addictions
8. Scientists turn a new leaf to discover a compound in daffodils that targets brain cancer
9. OHSU research suggests compound administered during some bone marrow transplants elevates risks
10. New investigational compound targets pancreatic cancer cells
11. Compounds in non-stick cookware may be associated with elevated cholesterol in children and teens
Post Your Comments:
(Date:6/27/2016)... ... 2016 , ... The OSHA Training Center at Chabot-Las ... headquartered in Northern California, has issued an important reminder to employers to prevent ... Employers with workers exposed to high temperatures should establish a complete heat illness ...
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution ... the emergency ambulance transport experience for the millions of people who require these ... disrupted the taxi industry through the use of technology. Now, SmartEMS has put ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
Breaking Medicine Technology: